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Abstract
SARS-CoV-2 infections elicit a humoral immune response capable of neutralising the virus. However, multiple variants have 
emerged with mutations in the spike protein amongst others, the key target of neutralising antibodies. We evaluated the neu-
tralising efficacy of 89 serum samples from patients, infected with SARS-CoV-2 in the beginning of 2020, against two virus 
variants isolated from acutely infected patients and harbouring spike protein mutations. One isolate was assigned to lineage 
B.1.351 (MUC-IMB-B.1.351) whilst the other (MUC-484) was isolated from an immunocompromised patient, sharing some 
but not all mutations with B.1.351 and representing a transitional variant. Both variants showed a significant reduction in 
neutralisation sensitivity compared to wild-type SARS-CoV-2 with MUC-IMB-B.1.351 being almost completely resistant to 
neutralisation. The observed reduction in neutralising activity of wild-type-specific antibodies against both variants suggests 
that individual mutations in the spike protein are sufficient to confer a potent escape from the humoral immune response. In 
addition, the effect of escape mutations seems to accumulate, so that more heavily mutated variants show a greater loss of 
sensitivity to neutralisation up to complete insensitivity as observed for MUC-IMB-B.1.351. From a clinical point of view, 
this might affect the efficacy of (monoclonal) antibody treatment of patients with prolonged infections as well as patients 
infected with variants other than the donor. At the same, this could also negatively influence the efficacy of current vaccines 
(as they are based on wild-type spike protein) emphasising the need to thoroughly surveil the emergence and distribution of 
variants and adapt vaccines and therapeutics accordingly.
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Introduction
SARS-CoV-2 has steadily changed its genome through 
mutations during its global spread amongst humans. Such 
mutations can in principle affect the entire viral genome. 
Of particular interest, though, are those that occur in the 
spike (S) protein are of particular interest, since this protein 
is responsible for binding to the human ACE2 receptor and 
is thus indispensable for virus cell entry. It is therefore not 
surprising that the S protein and in particular its receptor 
binding domain has been identified as the key target for elic-
iting potent neutralising antibodies (NAbs), likely protecting 
against reinfection [1, 2]. Moreover, the therapeutic admin-
istration of monoclonal antibodies (mAbs) and convales-
cent plasma from recovered patients is successfully applied 
worldwide.
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However, several novel variants that have recently 
emerged harbour a number of mutations, some of which 
are in the gene encoding the S protein [3]. This has sparked 
questions about their humoral immune evasion potential 
and the protective capability of wild-type (WT)-specific 
NAbs against such virus variants. In this context, we ana-
lysed serum samples from convalescent plasma donors 
infected with SARS-CoV-2 at the onset of the pandemic 
(April–May 2020) and found a significant reduction in 
neutralising activity (47.7%) when tested against Variant 
of Concern (VOC) B.1.1.7 (Alpha), confirming humoral 
immune evasion, at least to some extent [4]. To investi-
gate this finding further, we reevaluated these samples and 
tested their neutralising effect on another VOC, B.1.351 
(Beta), isolated from an acutely infected patient (MUC-
IMB-B.1.351). In addition, we also tested the neutralising 
capability of WT-specific NAbs against a SARS-CoV-2 
strain (MUC-484), which originated in an immunocom-
promised patient during the course of a prolonged infec-
tion with multiple therapeutic plasma donations and was 
first described by Khatamzas et al. [5]. The previously 
described and early circulating strain MUC-IMB-1 (clade 
B1) served as WT reference virus [6].
Lineage B.1.351 (Beta), also known as 20H/501Y.V2, 
is one of multiple SARS-CoV-2 variants circulating glob-
ally and is classified as a VOC by the WHO [7]. It was 
first identified in South Africa and whilst it shares some 
mutations with B.1.1.7, it emerged independently [8]. It 
has a well described asparagine to tyrosine substitution 
(N501Y), which is also present in VOCs belonging to 
the B.1.1.7 and P.1 lineages [9]. In addition, it also hosts 
two other mutations E484K and K417N, both located in 
the ACE2 interaction surface of the S protein [10]. Inter-
estingly, E484K was originally absent in B.1.1.7 includ-
ing the strain we tested in our previous study. It was not 
until later that some B.1.1.7 isolates also acquired this 
particular mutation (commonly referred to as “B.1.1.7 
enhanced”) which was shown to reduce the sensitivity to 
WT Nabs of these enhanced isolates, allowing for an even 
greater humoral immune evasion [9]. Current studies sug-
gest that this variant is more transmissible, likely due to 
carrying the early described D614G mutation associated 
with increased infectivity and has a significantly reduced 
susceptibility to various monoclonal antibody treatments 
as well as NAbs [11–14].
MUC-484 has several mutations, four of which are 
located within the S protein, including the D614G mutation. 
Most notably, the strain also acquired the E484K mutation 
present in B.1.351. However, it contains neither the above-
mentioned N501Y nor the K417N mutation, making it an 
interesting variant to investigate the influence of E484K in 
absence of N501Y and K417N compared with the more 
recent line B.1.351, which contains all three mutations.
Materials and methods
Origin of serum samples
As previously described [4], all samples were from 
patients which were hospitalised for their SARS-CoV-2 
infection, but did not require mechanical ventilation. All 
samples were collected, according to the official guidelines 
of the German Federal Institute for Vaccines and Biomedi-
cine [15] for the selection of plasma donors, 4 weeks after 
complete recovery. All had a serological profile consistent 
with recent SARS-CoV-2 infection (IgA/IgG antibodies, 
data not shown). Initially, 89 samples were tested against 
MUC-IMB-1 and MUC-B.1.351. However, nine samples 
were completely used up in the process, leaving only 80 
samples to be tested against MUC-484.
Isolation of SARS‑CoV‑2 variants
Replication competent SARS-CoV-2 was isolated from a 
nasopharyngeal swab of a patient diagnosed with COVID-
19 by quantitative PCR with reverse transcription (RT-
qPCR). Whole genome sequencing of this isolate (from 
now on referred to as MUC-IMB-B.1.351) was performed 
in accordance with the German Regulation for molecu-
lar genetic surveillance of the coronavirus SARS-CoV-2. 
The second isolate (from now on referred to as MUC-484) 
derived from an immunocompromised patient and was pre-
viously described [5]. NGS sequencing and phylogenetic 
analyses of both SARS-CoV-2 isolates were performed 
as previously described [16]. Lollipop plots were subse-
quently generated using R in combination with the track-
Viewer libaray [17].
Both viruses were grown on Vero E6 cells. Viral stocks 
were prepared, titrated and stored at − 80 ℃ until further 
use.
Micro‑neutralisation test
SARS-CoV-2 NAb titres were determined as previously 
described [18]. In brief, serum samples were serially 
diluted in duplicate in 96-well tissue culture plates start-
ing at 1:5 to a maximum if 1:640 along with positive and 
negative control samples. Virus stocks (50 TCID/50 µl) 
of B.1.351, MUC-484 and MUC-IMB-1 were prepared 
on Vero E6 cells; aliquots were stored at − 80 ℃ until fur-
ther use. Each Virus was pre-incubated (1 h, 37 ℃) with 
diluted samples before Vero E6 cells (1 ×  104 cells/50 µl) 
were added to each well. After 72 h (37 ℃), supernatants 
were discarded and wells were fixed (13% formalin/PBS) 
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and stained with 0.1% crystal violet. The NAb titre cor-
responded to the reciprocal of the highest sample dilution 
showing complete inhibition of CPE. A virus re-titration 
was performed in triplicates on every plate and exact titres 
were determined by retrograde calculation.
Results
Mutational changes in MUC‑IMB‑B.1.351
We were able to generate a high-quality genome from a 
patient sample containing replication competent SARS-
CoV-2. The isolated genome holds 29,903 nucleotides in 
length, which equals 100% of the SARS-CoV-2 genome. 
The theoretically obtained sequencing depth was 1536-fold. 
Sequencing analysis revealed 26 nonsynonymous mutations 
relative to the Wuhan sequence, assigning the isolate to the 
lineage B.1.351. An overview of all mutations is shown in 
Fig. 1A. Most notably, ten of the 26 mutations are located 
within the S protein. Prominent S-specific mutations include 
the amino acid changes K417N, E484K, N501Y and D614G. 
Moreover, amino acid changes D80A, D215G as well as the 
in-frame deletion 240∆LLA are present in the N-terminal 
domain (NTD) of the S protein.
As shown in Fig. 1B, MUC-484 contains only three non-
synonymous mutations in the S protein, including D614G, 
E484K and an in-frame deletion (143∆Y). In contrast to 
both variants, reference strain MUC-IMB-1 only has two 
nonsynonymous mutations present in its entire genome, one 
of which is located in the S protein (D614G) and also present 
in the other strains used in this study (Fig. 1C).
Sensitivity of MUC‑IMB‑B.1.351 to sera 
from convalescent plasma donors
Of the 89 samples tested, 73 were able to neutralise WT 
SARS-CoV-2 whilst for the remaining 16 samples no neu-
tralising activity could be observed. Direct comparison of 
NAbs titres against MUC-IMB-1 and MUC-IMB-B.1.351 
revealed that the vast majority of these positive serum sam-
ples (64/73) was unable to neutralise MUC-IMB-B.1.351. 
For the nine samples that partly retained their neutralising 
ability, a notable reduction was observed with a median 
decrease of 91.5% in neutralising activity. Altogether, 
the mean loss of neutralising activity against MUC-IMB-
B.1.351 was 99% and the observed decrease in titres was 
statistically significant (p < 0.0001 by Wilcoxon). At the 
same time, all samples (16/16) that initially tested negative 
for NAbs against WT virus were also unable to neutralise 
MUC-IMB-B.1.351 (Fig. 2).
Pearson regression analysis revealed only limited cor-
relation (r = 0.53; 95% CI: 0.37–0.67) between the NAb 
titre against WT SARS-CoV-2 and the titre against MUC-
IMB.1.351 of the same sample. (Fig. 3).
Fig. 1  Lollipop plots of all three SARS-CoV-2 strains examined in 
this study showing all nonsynonymous mutations in their respective 
genomes. A MUC-IMB-B.1.351 holds 26 mutations distributed over 
the genome. B MUC-484 shares only a few mutations with lineage 
B.1.351. C MUC-IMB-1 was used as WT SARS-CoV-2 reference 
strain
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Sensitivity of MUC‑484 to sera from convalescent 
plasma donors
Direct comparison of NAbs titres against WT and MUC-
484 showed that the majority of the tested serum samples 
(∑ = 80) was unable to retain their neutralising efficacy. Of 
the 64 samples that were able to neutralise MUC-IMB-1 
only one-third (20/64) was also able to neutralise MUC-484. 
At the same time, a notable reduction in NAbs titres was 
observed for 18 of these samples with a median decrease of 
89.6%. Two samples showed a slight increase in neutralisa-
tion when tested against MUC-484. A total of 44 samples 
showed no neutralisation when tested against MUC-484 
although they were able to neutralise WT SARS-CoV-2 in 
parallel control tests. Altogether, the median loss of neu-
tralising efficacy was 90.6%. All 16 samples that initially 
tested negative for NAbs against WT virus were also unable 
to neutralise MUC-484 (Fig. 4A & B). Overall, the observed 
drop in NAbs titres against MUC-484 compared to WT virus 
was statistically significant (p < 0.0001 by Wilcoxon).
Pearson regression analysis revealed very limited corre-
lation (r = 0.37; 95% CI: 0.17–0.55) between the NAb titre 
against WT SARS-CoV-2 and the titre against MUC-IM-
B.1.351 of the same sample (Fig. 5). As the changes in titre 
were highly variable, no prediction could be made about the 
neutralising efficacy of a serum against MUC-484 based on 
the titre against WT SARS-CoV-2.
Discussion
We investigated the sensitivity of an early circulating SARS-
CoV-2 and two mutation variants to sera from long-term 
convalescent plasma donors infected between April and May 
2020. Both variants harbour diverse mutations in the gene 
encoding the S protein, raising concerns about their humoral 
immune evasion potential. We used clinical viral isolates 
instead of pseudoviruses to include the effects of potentially 
relevant mutations outside the S protein. We isolated MUC-













































Fig. 2  Comparison of MUC-IMB-1 and MUC-IMB-B.1.351 dem-
onstrates a significant decrease in sensitivity towards NAbs (A) Side 
by-side comparison of NAbs titres against WT (orange) and MUC-
IMB-B.1.351 (purple). The greatest decrease was observed in a 
sample, which dropped from an initial titre of 177 to no neutralising 
effect against B.1.351 (red). (B) All but nine samples (blue) show a 
complete loss of neutralising activity (black). All samples that tested 
negative for NAbs against WT remained negative when tested against 
MUC-IMB-B.1.351 (grey). (∑ samples: 89, the number of overlap-
ping samples is shown in the respective circle)
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genome sequencing assigned the isolate to lineage B.1.351 
and revealed ten nonsynonymous mutations in the S pro-
tein relative to the original Wuhan sequence. MUC-484 
was isolated from an immunocompromised patient with a 
prolonged SARS-CoV-2 infection and was first described 
by Khatamzas et al. [5]. As shown, it holds three nonsynony-
mous mutations in the S protein. Early isolated MUC-IMB-1 
was used as WT reference strain with only two mutations in 
total, one of which is located in the S protein.
Substitution D614G is the only S mutation that is pre-
sent in all three strains examined in this study including 
the WT reference strain. It could therefore not be assessed 
with regard to its influence on neutralisation sensitivity. 
However, numerous studies suggest that the D614G muta-
tion increases overall fitness and infectivity but does not 
seem to promote immune evasion [19, 20]. Substitutions 
K417N, E484K, N501Y are commonly associated with 
VOCs and are of special interest as all of them have been 
shown to efficiently mediate antibody escape [13, 21]. 
MUC-484 only acquired the E484K mutation and was 
highly resistant to convalescent sera in our study with a 
median loss of neutralising efficacy of 90.6%. For com-
parison, we found a median decline of 99% for MUC-IMB-
B.1.351 carrying all three substitutions. These findings 
underline that the E484K mutation alone is vigorously 
reducing neutralisation sensitivity due to its enhancement 
of hACE2 binding whilst reducing the binding affinities 
of neutralising monoclonal antibodies [22]. At the same 
time, this also indicates that even a small number or even 
a single mutation in the S protein may be sufficient to 
significantly reduce antibody-mediated immune protection 
against SARS-CoV-2. This is also well in line with our 
recent report on the significant reduction of neutralising 
activity of the same sera against B.1.1.7. The observed 
decrease of 47.7% was less than the reduction we found 
for the variants tested in this study [4], which is likely 
because B.1.1.7 misses the vigorous E484K mutation and 
the observed antibody escape is mediated by N501Y only. 
Our observation that MUC-IMB-B.1.351 is even more 
resistant to neutralisation could be explained by the accu-
mulation of additional substitutions (including K417N and 
N501Y). It could also be an indication that S mutations act 
synergistically and their effect on each other is enhanced. 
In addition, the impact of NTD-specific antibodies on 
virus neutralisation has been described [23]. MUC-IMB-
B.1.351 carries mutations located within the NTD (i.e. two 
substitutions and one in-frame deletion) that were previ-
ously shown to influence NTD-specific NAbs [24]. Based 
on our findings, these mutations likely contribute to the 
neutralisation resistance of MUC-IMB-B.1.351 but appear 
to play a minor role.
In contrast, we were surprised by the finding that two sera 
showed increased neutralising activity against MUC-484 
(but not MUC-IMB-B.1.351). Interestingly, we observed 
the same phenomenon with one serum when tested against 
B.1.1.7 [4]. This could indicate that in rare cases polyvalent 
antibody formation could also improve neutralisation against 
variants. However, this could be contradicted by the fact that 
this effect was observed in different samples in each case. 
This is consistent with structural predictions showing that 
K417N and E484K inhibit the binding of different mono-
clonal antibodies and can therefore act synergistically in a 
polyclonal serum [22].
The fact that the E484K emerged independently in an 
immunocompromised patient with prolonged infection under 
plasma donation treatment [5] and is highly resistant to neu-
tralisation is particularly striking. It highlights the problem 
that it is not only necessary to monitor the emergence of var-
iants at the population level, but also for individual patients 
in some circumstances. Especially in severe and longstand-
ing COVID-19 cases, treatment with convalescent plasma 
seems to promote the emergence of escape variants and 
decrease the efficacy of plasma therapy over time [25, 26].
The fact that no prediction could be made about the neu-
tralising efficacy of a serum against either variant based 
on the NAbs titre of the same sample against WT SARS-
CoV-2 must be considered, especially for the therapeutic 
use of convalescent plasma. Ideally, the neutralising efficacy 
of convalescent plasma should be determined against the 
major virus clades circulating at that time and administered 
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Fig. 3  Correlation plot reveals limited correlation between NAbs 
titres against MUC-IMB-1 and MUC-IMB-B.1.351 No prediction 
can be made about the neutralising efficacy of a serum against MUC-
B.1.351 based on the NAbs titre of the same sample against WT 
SARS-CoV-2 and vice versa (r = 0.53, 95% CI: 0.37–0.67 Pearson 
regression analysis)
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possible. This includes that NAbs detection assays such as 
virus neutralization tests (VNT) or surrogate tests should be 
continuously adapted to cover current virus clades.
A potential limitation of our study is its relatively low 
number of tested samples as well the overall low titres of 
these samples, which might lead to an overestimation of the 
variants immune escape potential In addition, we could not 
include in our investigations the potentially pre-existing cel-
lular immune response, which might be more cross-reactive 
than NAbs. Thus, future studies focussing on the cellular 
immune response are needed.
Overall, our study highlights the humoral immune eva-
sion potential not only of globally circulating VOCs such 
as B.1.351 but also of variants emerging in patients under 
plasma therapy. Mutations of the S protein are of particu-
lar interest and we demonstrate that different mutations and 
combinations thereof can be associated with a reduction up 
to complete loss of neutralising antibody cross-reactivity 















































Fig. 4  Comparison of MUC-IMB-1 and MUC-484 demonstrates 
an overall decrease in sensitivity towards NAbs (A) Side-by-side 
comparison of WT (orange) and MUC-484 (blue) reveals an overall 
decrease in NAbs titre levels with the exception of only two samples 
depicted in green, showing a lowgrade increase in titre level from 11 
to 27.6 and 7.8 to 12.5, respectively. (B) Whilst one third of samples 
was still able to neutralise MUC-484 (blue), a notable decrease in 
titre levels can be observed for all but two of those samples with a 
median decrease of 97.1%. Two samples show an increase in neutral-
ising activity (green). The remaining two-thirds of the samples show 
a complete loss of neutralising efficacy against MUC-IMB-1 (black) 
whilst all 16 samples that tested negative for NAbs against MUC-
IMB-1 remained negative when tested against MUC-484 (grey). 
(∑ samples: 80; the number of overlapping samples is shown in the 
respective circle)
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